巨星醫療控股(02393.HK)自研84消毒液獲批投入生產 2月11日運往醫院
格隆匯2月11日丨巨星醫療控股(02393.HK)公佈,公司自行研發的環境消毒產品「84消毒液」已得到廣西壯族自治區衞生健康委員會批覆,正式投入生產,首批約5噸(稀釋倍數150倍)於2020年2月11日開始運往醫院。
公告顯示,「84消毒液」為公司自行研發的產品,適用於一般物體表面和環境的清潔與消毒,如:醫院、商場、學校、公園、小區、居家環境等終端應用。此項產品將透過公司直銷和經銷商體系推廣至醫院、商超、線上線下平台等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.